Final results of neoadjuvant trial of bevacizumab (B) and trastuzumab (T) in combination with weekly paclitaxel (P) as neoadjuvant treatment in HER2-positive breast cancer: A phase II trial (AVANTHER)

被引：0
|
作者：
Fernandez, M.
Calvo, I.
Martinez, N.
Herrero, M.
Quijano, Y.
Duran, H.
Garcia-Aranda, M.
Suarez, A.
-Rios, F. Lopez
Perez, D.
Perea, S.
Hidalgo, M.
Garcia-Estevez, L.
机构：
[1] Ctr Integral Oncol Clara Campal, Madrid, Spain
[2] Hosp Ramon & Cajal, E-28034 Madrid, Spain
[3] Hosp Costa del Sol, Marbella, Spain
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
10.1158/0008-5472.SABCS12-P1-14-10
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-14-10
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Neoadjuvant bevacizumab (B) and trastuzumab (T) in combination with weekly paclitaxel (P) as neoadjuvant treatment in HER2-positive breast cancer: Results from a phase II trial (AVANTHER)
    Fernandez Abad, Maria
    Calvo, Isabel
    Martinez, Noelia
    Herrero, Mercedes
    Quijano, Yolanda
    Duran, Hipolito
    Garcia Aranda, Mariola
    Suarez, Ana
    Lopez-Rios, Fernando
    Perez, Diego
    Perea, Sofia
    Hidalgo, Manuel
    Garca-Estevez, Laura
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [2] Neoadjuvant trial of bevacizumab (B) and trastuzumab (T) in combination with weekly paclitaxel (P) as neoadjuvant treatment in HER2-positive breast cancer: A phase II trial (AVANTHER). Analysis of biomarkers
    Fernandez, M.
    Martinez, N.
    Calvo, I.
    Garcia, E.
    Ugidos, L.
    Herrero, M.
    Quijano, Y.
    Duran, H.
    Garcia, M.
    Suarez, A.
    Lopez-Rios, F.
    Perez, D.
    Perea, S.
    Hidalgo, M.
    Garcia-Estevez, L.
    CANCER RESEARCH, 2013, 73
  • [3] A phase II trial of neoadjuvant epirubicin/cyclophosphamide followed by weekly nanoparticle albumin-bound paclitaxel with trastuzumab for HER2-positive breast cancer
    Kodera, A.
    Hirano, A.
    Inoue, H.
    Ogura, K.
    Hattori, A.
    Sakaguchi, S.
    Yukawa, H.
    Matsuoka, A.
    Tanaka, N.
    Kamimura, M.
    Jibiki, N.
    Fujibayasi, M.
    Naritaka, Y.
    Shimizu, T.
    CANCER RESEARCH, 2017, 77
  • [4] Phase II Trial of Neoadjuvant Pegylated Liposomal Doxorubicin with Paclitaxel and Trastuzumab in Patients with Operable Her2-Positive Breast Cancer
    Hyams, D. M.
    Leichman, G. C.
    Klein, P.
    Rietchsel, P.
    Levine, E. G.
    Gebski, V. J.
    Kelley, M. A.
    CANCER RESEARCH, 2009, 69 (24) : 570S - 570S
  • [5] A phase II neoadjuvant trial of concurrent trastuzumab and paclitaxel without anthracycline in women with HER2-positive operable breast cancer
    Jinno, H.
    Sato, T.
    Takahashi, M.
    Hayashida, T.
    Sakata, M.
    Hirose, S.
    Kitagawa, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [6] Clinical and translational results of CALGB 40601: A neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer.
    Carey, Lisa A.
    Berry, Donald A.
    Ollila, David
    Harris, Lyndsay
    Krop, Ian E.
    Weckstein, Douglas
    Henry, Norah Lynn
    Anders, Carey K.
    Cirrincione, Constance
    Winer, Eric P.
    Perou, Charles M.
    Hudis, Clifford
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [7] A phase II neoadjuvant trial of concurrent trastuzumab and paclitaxel without anthracycline in women with HER2-positive operable breast cancer.
    Jinno, H.
    Hayashida, T.
    Takahashi, M.
    Hirose, S.
    Kitagawa, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (27)
  • [8] Nab-paclitaxel and trastuzumab combination: a promising approach for neoadjuvant treatment in HER2-positive breast cancer
    Ricciardi, Giuseppina Rosaria Rita
    Franchina, Tindara
    Russo, Alessandro
    Schifano, Silvia
    Ferraro, Giuseppa
    Adamo, Vincenzo
    ONCOTARGETS AND THERAPY, 2016, 9 : 4351 - 4355
  • [9] A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer
    Adrienne G. Waks
    Neelam V. Desai
    Tianyu Li
    Philip D. Poorvu
    Ann H. Partridge
    Natalie Sinclair
    Laura M. Spring
    Meredith Faggen
    Michael Constantine
    Otto Metzger
    Jillian Alberti
    Julia Deane
    Shoshana M. Rosenberg
    Elizabeth Frank
    Sara M. Tolaney
    Ian E. Krop
    Nadine M. Tung
    Nabihah Tayob
    Tari A. King
    Elizabeth A. Mittendorf
    Eric P. Winer
    npj Breast Cancer, 8
  • [10] A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer
    Waks, Adrienne G.
    Desai, Neelam V.
    Li, Tianyu
    Poorvu, Philip D.
    Partridge, Ann H.
    Sinclair, Natalie
    Spring, Laura M.
    Faggen, Meredith
    Constantine, Michael
    Metzger, Otto
    Alberti, Jillian
    Deane, Julia
    Rosenberg, Shoshana M.
    Frank, Elizabeth
    Tolaney, Sara M.
    Krop, Ian E.
    Tung, Nadine M.
    Tayob, Nabihah
    King, Tari A.
    Mittendorf, Elizabeth A.
    Winer, Eric P.
    NPJ BREAST CANCER, 2022, 8 (01)
12345